Introduction
This is a malignant proliferation of plasma cells. Normal plasma cells are derived from B cells and produce immunoglobulins which contain heavy and light chains. Normal immunoglobulins are POLYCLONAL, but in myeloma plasma cells produce immunoglobulin of a single heavy and light chain, a MONOCLONAL protein called as paraprotein.
In some cases only light chain is produced and this appears in the urine as BENCE JONES PROTEINURIA.
The malignant plasma cells produce cytokines, which stimulates osteoclasts and result in net bone reabsorption which causes bone pain, fractures and hypercalcaemia.
Clinical features and investigations
Bone pain/ fractures
Lytic lesions
Nephrotic syndrome, carpal tunnel syndrome
Panda eyes
Renal failure due to paraprotein deposition, hypercalcaemia, infection, NSAIDs, amyloid.
Spinal cord compression
Retinal bleeds
Bruising
Heart failure
Cerebral ischaemia
Diagnosis of myeloma requires two of the following criteria:
1. Increase malignant plasma cells in bone marrow
2. Serum and/ or urinary M-protein
3. Skeletal lytic lesions.
Investigations
X-ray for skeletal survey
Alkaline phosphatase
MRI spine
Blood and urine protein electrophoresis done for the presence of M-protein
Blood and urine IMMUNOELECTROPHORESIS for the TYPE of M-protein
Bone marrow aspiration and trephine
Full blood count
Urea, creatinine, urate and electrolytes to access renal function
Blood calcium and albumin to know presence of hypercalcaemia.
Management
Immediate support
• High fluid intake to treat renal impairment and hypercalcaemia.
• Analgesia for bone pain.
• Bisphosphonates for hypercalcaemia.
• Allopurinol to prevent urate nephropathy.
• Plasmapheresis for hyperviscosity.
Chemotherapy with or without HSCT
First line treatment is with THALIDOMIDE and more recently with the BORTEZOMIB.
Thalidomide along with the alkylating agent MEPHALAN and PREDNISOLONE has increased the median overall survival to more than 4 years.
Treatment is administered untill PARAPROTEIN levels have stopped falling. This is termed as PLATEAU PHASE.
In UK at present, bortezomib is recommended followed by LENALIDOMIDE if there is subsequent progression.
Radiotherapy
This is effective for localised bone pain not responding to simple analgesia.
Bisphosphonates
Long term therapy reduces bone pain and skeletal events.
I/V ZOLEDRONATE in combination with anti-myeloma therapy confers a survival advantage over oral bisphosphonates.
Comments
Post a Comment
Please do not enter any spam link in the comment box.